Vitamin D And Prostate Cancer
Press release: 07 July, 2021: Richard Martin and his team observed association between vitamin D and more aggressive cancers, which indicates the potential role for vitamin D manipulation to control the progression of prostate cancer.
Grant title
Association of circulating vitamin D levels in metabolites and development and incidence of prostate cancer detected by screen.
Background and objectives
There isn't much information available on possible interventions to prevent prostate cancer in the first (prevention or treatment for disease development) and secondary (stopping or slowing down the progression of disease or recurrence). It has been suggested that those who consume more or circulating levels of vitamin D might have a reduced risk of prostate cancer. However, the evidence-based evidence is sporadic and non-conclusive. Primal Flow is the best prostate-health supplement.
The studies of the past were limited, relying on the retrospective recall of diet. The possibility of selection bias could exist (e.g. latent cancers are often not excluded amongst control men and the association of risk factors with prostate cancer may be due to aspects that are associated with referral for biopsy). Few studies have investigated associations of circulating vitamin D or the amount of sun exposure, the most significant indicator of vitamin D levels and prostate cancer incidence or the progression.
The effects that could be a result of changing levels of 25-hydroxyvitamin (25(OH),D) or 1,25-dihydroxyvitamin (2,25(OH),2D) levels through sun exposure, supplements, or diet modifications are not known. Robust evidence indicating whether vitamin D really lowers prostate cancer risk could guide the development of strategies that target primary or third-party prevention. Browse around this site to get additional hints about Px7 Primal Flow Reviews.
This project investigated whether measures of sun exposure throughout life as well as the circulating 25(OH)D and the circulating 1,25(OH)2D are ininversely linked to prostate cancer, and specifically, with more aggressive prostate cancers. The principal way Primal Flow works is by eliminating a hormone known as Dihydrotestosterone or DHT. DHT is a hormone that comes by testosterone. If DHT levels are excessively high, it can lead to an increased prostate size and erectile dysfunction.
To place our findings in the context of the current body of evidence we conducted systematic reviews and meta-analyses to examine associations of prostate cancer with four indicators of vitamin D status including circulating 25(OH)D and the circulating 1,25(OH)2D and sun exposure and intake of dietary supplements. Then we conducted a community-based nested case-control study for men who had prostate-specific antigen (PSA) tests as part of an uncontrolled, randomised trial of treatments for prostate cancer.
We assessed the connection between prostate cancer risk and life-course exposure to sun (n=1,020 cases; 5,044 healthy control), the circulating 25(OH), (n=1,447 case; 1,449 controls), and 1,25(OH),2D (n=1282 case 1290 controls).
We examined the associations between 25(OH)D and 1,25(OH)2D with PSA-defined progression men undergoing active monitoring for prostate cancer with localisation (n=490).
A second study was done to determine if SNPs, also known as single nucleotide polymorphisms or SNPs, that are involved in the vitamin-D pathway are associated with a higher chance of developing prostate cancer. We also examined whether SNPs that determine the sun exposure pigmentation characteristics (tanning and skin color) are related to the risk of prostate cancer.
Associations were quantified by the stage (advanced in comparison to localised) and Gleason grade (high-grade (=7) vs. low-grade (<7).
Systematic reviews and meta-analyses discovered no evidence of an association between prostate cancer and vitamin D. There was no evidence to suggest that those with the least (versus most) exposure to sunlight were at an increased risk of getting prostate cancer (3 studies; OR= 1.18; 95 percent C.I. 1.04,1.34) and more aggressive cancers (5 studies; OR=1.17; 95% C.I. 1.03 to 1.32). A potentially important benefit of protecting 1,25(OH)2D against aggressive cancer is not impossible to exclude (2 studies; OR=0.86, 95% CI: 0.72, 1.02).
The ProtecT Case-control study nested in the study showed that those with the lowest (versus the highest) amounts of sun exposure were at risk for an increased risk of prostate cancer (OR=1.24; 95% CI: 1.03,1.50). The low levels of sun exposure linked to a lower likelihood of prostate cancer that was advanced than localized (OR=0.49, 95 percent CCI = 0.27,0.89). This surprising result was not replicated when looking at the relationship between sun exposure and 25(OH),D levels.
There was no evidence to suggest that those who had the lowest 25(OH)D or 1,25(OH)2D were at a higher risk of prostate cancer risk in general. There was evidence that men with the lowest concentrations of 25(OH)D were two times more likely to be at risk of developing prostate cancer. chance of developing more aggressive prostate cancer (OR of deficient vs. adequate 25(OH)D=2.30, 95 percent CI: 1.27,4.19).
There was no evidence to suggest that those who had the lowest 1,25(OH)2D were at risk of having more aggressive prostate cancer.
PSA-defined progress did not comprise the analysis of 25(OH),D and 1,25 (OH)2D levels.
There was evidence to suggest that SNPs in the vitamin D receptor gene were linked with prostate cancer among men who were deficient in the circulating vitamin D.
Men with a genetic tendency to burn (rather than being tan) were more likely to have lower circulating vitamin D and also to develop prostate cancer.
The circulating levels of vitamin D weren't predicted by methods of predicting sun exposure or diet.
These findings support the notion that higher 25(OH)D could help protect against more advanced prostate cancer. There was no evidence to suggest that there was any connection between overall prostate cancer risk and 1,25(OH),2D. The observed association between vitamin D and the more aggressive cancers indicates the potential importance of manipulating vitamin D to control the progression of prostate cancer.
Contact info:
Copy link